PREVALENCE OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND ANTIMICROBIAL SUSCEPTIBILITY PATTERNS AT A PRIVATE HOSPITAL IN SANA'A, YEMEN

Ali Alyahawi1*, Ali Alkaf2, Abdul Monem Alhomidi3

1Department of Pharmacy, Faculty of Medical Sciences, Al-Razi University, Republic of Yemen

2Faculty of Pharmacy, Sana'a University, Republic of Yemen

3Faculty of Medicine, Sana'a University, Republic of Yemen

DOI: https://doi.org/10.22270/ujpr.v3i3.159

INTRODUCTION

Staphylococcus aureus is one of the most important pathogens affecting humans. Penicillin is the drug of choice to treat infections caused by Staphylococcus aureus. Because of the penicillin was commonly prescribed drugs, the prevalence of penicillin resistant strains increased, especially in hospitals1. MRSA was first described in 1961. It was reported after one year of introduction of methicillin. Recently, it was defined as one of the most important nosocomial pathogens. New studies suggest that the infection due to MRSA is not only hospital-acquired but community acquired as well2. Also MRSA has become a major public health problem worldwide3. Some large outbreaks of MRSA have been documented from different regions of the world, where it had caused severe infections including septicemia, endocarditis and meningitis4.

A study by Dickinson in England and Wales has approved an increase in the death rate of MRSA infection5.The risk factors that increase in MRSA prevalence are antibiotics abuse, prolonged hospitalization, intravascular instrumentation and hospitalization in an intensive care unit. There is significant variation in prevalence of clinical infections among units, hospitals and countries4. MRSA is of serious concern because of resistance to many other antimicrobials that are commonly used in hospitals. Another important element was that emergence of resistance to vancomycin, although at a low level has been documented6. Significantly, the Netherlands and countries in the Scandinavian region, had maintained low rates of MRSA infection due to strict infection control practices7. The problem of MRSA continues to increase and the rising colonization rates lead to the increasing of infection rates in the public and in hospitals. This can increase hospital stays and greater costs of the health care system8. Appropriate selection of empiric antibiotics for infections, depending on local circulating pathogens, can lead to good patient outcomes. So, epidemiologic information collected through ongoing surveillance is important to support clinicians and infection control committees to prevent and treat infection7.The hospitals of different sizes were facing the problem of MRSA. In addition, the problem of MRSA appears to be increasing regardless the size of hospital and its control measures for MRSA8. The aim of the present study is the detection of MRSA from various clinical departments at a local private hospital in Sana'a, Yemen and determining their susceptibility to some antimicrobial agents.

 METHOD

The current retrospective study based on electronic laboratory records of Staphylococcus aureus isolates and MRSA isolates from clinical specimens analyzed at microbiology laboratory of university of sciences and technology (UST) hospital in Sana’a, Yemen. The records were taken from the microbiology department. Staphylococcus strains were identified based on Gram's stain morphology, colony characteristics, and biochemical identification tests. All isolates were identified as S. aureus according to standard methods9. A total of 2079 isolates were collected from the hospitalized patients in hospital of UST from January 2017 to December 2017. These isolates were obtained through conventional clinically oriented ordered cultures. From 2079 isolates, a total of 199 isolates were S. aureus strains. Methicillin resistance was determined using methicillin screening. All isolates were from inpatients’ clinical specimens (mainly respiratory secretion, pus, urine, and blood) and Standard isolation procedures were applied to all the samples.

Antibiotic susceptibility testing was done by Kirby Bauer's Disc diffusion technique, following Clinical and Laboratory Standards Institute (CLSI)9. The antimicrobial susceptibility patterns of all the MRSA strains were determined against the following antibiotics: vancomycin, linezolide, imipenem, levofloxacin, ciprofloxacin, cotrimoxzole, Erythromycinamoxicillin/ clavulinic Acid, cefuroxime, doxycycline, clindamycin, ampicillin/ sulbactam, gentamicin, moxifloxacin, and lincomycin. Full ethical clearance was obtained from the qualified authorities who approved the study design. All data were analyzed using SPSS Statistics 21. Data was presented in tables and graphs.

RESULTS

The Figure 1 showed highest numbers of Staphylococcus aureus were obtained from pus (n=81/199; 40.7%) and least from urine (n=11/199; 5.5%). In this study, overall MRSA prevalence was 17.6 % (n=35/199; 17.6). The study results showed that the most of the  MRSA isolates prevalence in age group between 46 to 60 years about 12(34%), followed by the age more than 60 years in second rank about 8 (23%), and finally the age between 1 to 15 or years only about 2(6%). The Figure 3 showed that the most of the MRSA isolates were in male about 29(83%), whereas the female participants only about 6(17%). According to the study findings, ICU and surgical departments had the same and most prevalence of MRSA about 10(29%), followed by the medical and laboratory departments with rank about 6(17%), and finally the neurological department only about 3(8 %). The Figure 5 showed that more than half of MRSA isolates from sputum culture about 18(51.4%), followed by the wound swab culture about 12(34.3%), and finally blood culture only about 2(5.7%).

In this study, the most of medication that had resistance to MRSA test were about 12 drugs (80%), whereas the medication that sensitive to MRSA test about 3 drugs (20%). Also the study results showed that MRSA isolates were resistant to levofloxacin 100 %, amoxicillin/clavulinic acid100%, moxifloxacin 76 %, gentamicin 94 %, clindamycin 70.5%, ciprofloxacin 97%, cefuroxime 91 % erythromycin 71.5%, and ampicillin/ sulbactam 94%. The highest frequency of sensitivity (100 %) was observed with trimethoprim/sulfamethoxazole, linezolide, and Vancomycin (table1). The Table 2 showed there were no statistical significant relationship between the usage of vancomycin and linezolid age group (P value = 0.74, 0.44). The Table 3 showed there were no statistical significant relationship between the sensitivity pattern of vancomycin and linezolid hospital department (P-value = 0.63, 0.35). Also the study findings showed that there was no statistical significant relationship between the sensitivity pattern of vancomycin and linezolide and sample type (P value= 0.80, 0.23).

DISCUSSION

Recently, the prevalence of MRSA hassteadily increased worldwide4. In addition, the antimicrobial susceptibility pattern of MRSA strains should be described. In our study, most S. aureus strains (n=81/199; 40.7%) were isolated from pus specimen. This is consistent with a previous study done in Nairobi10. In a study done to determine the antimicrobial susceptibility pattern of S. aureus strains isolated from hospitalized patients in Iran, most of the isolates were from blood specimens (29%)11. Another study done on prevalence and antibiotic susceptibility pattern of S. aureus from clinical isolates in Nigeria showed a majority of the isolates were from urine specimens (76%)12. The high number of S. aureus isolated in pus may be attributed to exposure of wounds which makes them more prone to infections and poor hygiene. In this study, overall MRSA prevalence was 17.6 % (n=35/199; 17.6). This prevalence was lower than in previous studies that reported 31.5%13 and 46.3%14. This difference could be due to various interventions during the study period such as infection control and appropriate antibiotic usage14,15. Also MRSA prevalence was higher in studies done in two private hospitals in Nairobi, Kenya, which showed a 3.8% prevalence16. In addition, a study in Eritrea reported 0.03% of prevalence in Dutch hospitals (17). This approved there is high variance of MRSA prevalence from different countries. The low prevalence of MRSA in private hospitals could be attributed to better infection controls14. According to current study results, majority of MRSA was isolated from sputum specimens, 18/35 (51.4%). In contrast to study findings in Nigeria6, and Iran11 showed different specimens were predominant. This variation in prevalence may be because of several factors like healthcare facilities available in the particular hospital, implementation and monitoring of infection control committee, rationale antibiotic usage which varies from hospital to hospital14,15.

In this study, 100% of MRSA isolates were sensitive to vancomycin. This finding is similar to a study done on antimicrobial susceptibility of MRSA in hospitalized patients in Iran, two hospitals in India and two private hospitals in Kenya showed 100% susceptibility to vancomycin17,18,10. On other hand, studies done in Iran19 which showed 5% of the MRSA isolates were resistant to vancomycin and in a tertiary care hospital in India20 and pediatrics and neonatal intensive care patients at Nairobi which respectively showed 3.5 and 1% resistance to vancomycin among MRSA6. Recently, many antibiotics with anti-MRSA activity were introduced to the market, some of which are available in Yemen. Linezolid is among these agents which is not widely available and it is not in use in many Yemeni hospitals including the setting of this study. In the present study, 100% of MRSA isolates were sensitive to linezolid. Garcia et al. have reported the first clinical outbreak of linezolid resistant S. aureus (LRSA) from a tertiary teaching university hospital in Madrid, Spain21. In their article they reported 12 patients with LRSA from which 6 patients died (with one death ascribed to LRSA infection). In the last two decades prevalence of MRSA has steadily increased worldwide. Therefore, they stated that this increase was associated with nosocomial transmission and extensive use of this antibiotic22.

In this study, the results showed that MRSA isolates were resistant to levofloxacin100 %, amoxicillin/ clavulinic acid100%, moxifloxacin 76%, gentamicin 94%, clindamycin 70.5%, ciprofloxacin 97%, cefuroxime 91% erythromycin 71.5%, ampicillin/ sulbactam 94%, and imipenem 55%. The highest frequency of sensitivity (100 %) was observed with trimethoprim/ sulfamethoxazole, linezolide, and vancomycin. Multidrug- resistance made the treatment of MRSA more difficult. This may be due to dispensing antibiotics without prescription and inappropriate selection of antibiotics for infections as empirical treatment worldwide. Also the use of broad-spectrum antibiotics for treating infections such as imipenem may be increase the rate of MRSA and other resistant pathogens, so a more careful monitoring of antibiotics should be instituted. Vancomycin is the universally accepted drug of choice. We found all MRSA isolates to be susceptible to vancomycin. Similar results have been reported by other authors23,24. Resistant to quinolones (Levofloxacin, ciprofloxacin, and moxifloxacin) was high (100, 97%, and 76%; respectively) in the present study. In a previous study25, the resistant rate was also high (87.5%), but another study26 conducted in 2003, reported the resistant rate of ciprofloxacin to be only 32.6%. The rapid emergence of quinolones was probably due to the indiscriminate empirical use of these drugs. An important finding of the present study was that the MRSA cases from ICU accounted for 17.6 % of all cases. Our finding was in agreement with the findings of Dominique et al.27 from Switzerland. Also slightly higher than study conducted in 2003 from Nebal, reported the MRSA cases from ICU were only 10% from all MRSA cases37. A European study on prevalence of MRSA infection on samples from intensive care, estimated close to 65%28. In the present study, the low prevalence of MRSA, which included clinical samples from all hospital wards, illustrated the efficacy of relatively good infection control practice in the study setting. Also maximum resistance was seen with ampicillin-sulbactam, amoxicillin-clavulanicand gentamicin (Table 3). Similar results were obtained in a previous study29. In addition, resistance was also seen with cefuroxime (91%), doxycyclin (91.2%), and erythromycin (71.5%). Gentamicin is a most commonly used drug, because of its low cost and synergistic activity with beta-lactam antibiotics. In the present study, 94% of gentamicin resistance was seen, which was slightly higher than a previous study30. Most common reason for multidrug resistant MRSA is indiscriminate use of antibiotics without drug sensitivity testing which may be due to lack of advanced laboratory facilities or negligence on the part of medical practitioners or patients poor economic status. Also this is due to the fact that MRSA is often multidrugresistant6.

Although vancomycin seems to be the only antimicrobial agent who showed 100% sensitivity and may be used as the drug of choice for treating multidrug-resistant MRSA infections, vancomycin is not a commonly prescribed drug, which is almost due to the higher nephrotoxic antibiotic and its unavailability in many parts of the country. The control of MRSA transmission seems to be the only hope to complete eradication of MRSA. The most effective way to control MRSA is good hand hygiene along with environmental cleaning of hospital rooms to reduce nosocomial rates of infection7.The results of current study showed that there were highly susceptible to newer drugs such as linezolid. This finding differs from a study done by Arian poor et al. in Iran which showed 5.5% of MRSA isolates were resistant to linezolid19.

CONCLUSION AND RECOMMENDATIONS

The present study showed a low level prevalence of MRSA. Also MRSA isolates were highly susceptible to newer drugs such as linezolid and to vancomycin which is not a commonly prescribed drug due to the higher nephrotoxic antibiotic. Also this study showed that ICU and surgical wards had the highest proportion of MRSA isolates of hospital departments. Information from this study may be used in future as a baseline for follow-up to the susceptibility trend of various drugs to be used for the treatment of S. aureus infections. Routine screening of MRSA and regular studies should be conducted to predict the trend of MRSA.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

  1. Perwaiz S, QamaruddinBarakzi Q, Farooqi BJ, Khursheed N, Sabir N. Antimicrobial susceptibility pattern of clinical isolates of Methicillin Resistant Staphylococcus aureus. Karachi. 2007; 57: 1.
  2. Maple PAC, Hamilton-Miller JMT, Brumfitt W. Worldwide antibiotic resistance in methicillin resistant Staphylococcus aureus. Lancet. 1989; 1:537-40.
  3. Jarvis WR, Schlosser J, Chinn RY, Tweeten, S, and Jackson, M. National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities. Am. J Infect Control. 2007; 35: 631- 637.
  4. Kumari N,Mohapatra TM, Singh YI. Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA) in a Tertiary-Care Hospital. J Nepal Med Assoc. 2008;47(170):53-6
  5. Dickinson E. Mortality from methicillin–resistant Staphylococcus aureus in England and Wales: analysis of death certificates. BMJ. 2002; 325:1390-1.
  6. MIR BA, Srikanth. Prevalence and antimicrobial susceptibility of methicillin resistant Staphylococcus aureus and Coagulase-Negative Staphylococciina Tertiary Care Hospital. Asian J Pharm Clin Res. 2013; 6(3):231-234.
  7. Mejía CZurita JGuzmán-Blanco M. Epidemiology and surveillance of methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis.2010; 14(2):79-86.  
  8. Al-Dahbi and Al-Mathkhury. Distribution of Methicillin Resistant Staphylococcus aureus in Iraqi patients and Healthcare Workers. Iraqi J Science. 2013; 54 (2):293-300.
  9. Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement, Clinical and Laboratory Standards Institute (CLSI) M100-S20: 30:1: Clinical and Laboratory Standards Institute; 2012.
  10. Kanaga EL. Antimicrobial susceptibility of bacteria that cause wound sepsis in the paediatricsurgica. Wayne, PA l patients at Kenyatta national hospital. 2014; http://erepo sitory.uonbi .ac.ke/handl e/11295 /95412. Accessed 7 Sept 2017.
  11. Soltani R, Khalili H, Rasoolinejad M, Abdollahi A. Antimicrobial susceptibility pattern of Staphylococcus aureus strains isolated from hospitalized patients in Tehran, Iran. Iran J Pharm Sci. 2010; 6:125–32.
  12. Obiazi HAK, Ekundayo AO, Ukwandu NCD. Prevalence and antibiotic susceptibility pattern of Staphylococcus aureus from clinical isolates grown at 37 and 44°C from Irrua, Nigeria. African J Microbiol Res. 2007; 1:57–60.
  13. Ojulong J, Mwambu TP, Joloba M, Bwanga F, Kaddu-Mulindwa DH. Relative prevalence of methicilline resistant Staphylococcus aureus and its susceptibility pattern in Mulago Hospital, Kampala, Uganda. Tanzan J Health Res. 2009; 11:149–53.
  14. Dibah S, Arzanlou M, Jannati E, Shapouri R. Prevalence and antimicrobial resistance pattern of methicillin resistant Staphylococcus aureus (MRSA (strains isolated from clinical specimens in Ardabil, Iran. Iran J Microbiol. 2014; 6:163–8.
  15. Funke G, Funke-Kissling P. Performance of the new VITEK 2 GP card for identification of medically relevant Gram-positive cocci in a routine clinical laboratory. J Clin Microbiol. 2005; 43:84–8.
  16. Omuse G, Kabera B, Revathi G. Low prevalence of methicillin resistant Staphylococcus aureus as determined by an automated identification system in two private hospitals in Nairobi, Kenya: a cross sectional study. BMC Infect Dis. 2014; 14:669.
  17. Wertheim HFL, Vos MC, Boelens HAM, Voss A, Vandenbroucke-Grauls CMJE, Meester MHM. Low prevalence of methicillin-resistant Staphylococcusaureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect. 2004; 56:321–5.
  18. Crowley E, Bird P, Fisher K, Goetz K, Boyle M, Benzinger MJJ. Evaluation of the VITEK 2 gram positive (GP) microbial identification test card: collaborative study. J AOAC Int. 2012; 95:1425–32.
  19. Joshi S. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence and susceptibility pattern. Indian J Med Res. 2013; 137:363–9.
  20. Arianpoor A, Estaji F, Naderinasab M, Askari E. Antimicrobial susceptibility pattern of Staphylococcus aureus Isolates against newly marketed antibiotics. J Ayub Med Coll Abbottabad. 2015; 3:3–6.
  21. Rayner C, Munckhof WJ. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J. 2005; 35 (Suppl 2):3–16.,
  22. Sanchez Garcia M, De la Torre MA, Morales G, Pelaez B, Tolon MJ, Domingo S, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010; 303(22):2260– 4.
  23. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol. 1992; 13:582-6.
  24. Latif S, Anwar MS, Chaudary NA. Susceptibility Pattern of Nosocomial Methicillin Resistant Staphylococcus aureus (MRSA) Isolates to Vancomycin and other Anti-Staphylococcal Antibiotics. Biomedica. 2000; 16:32-517.
  25. Bukhari MH, Iqbal A, Khatoon N, Iqbal N, Naeem S, Qureshi G R, et al. A laboratory study of susceptibility of methicillin resistant Staphylococcus aureus (MRSA). Pak J Med Sci. 2004; 20:229–33.
  26. Saikia L, Nath R Choudhary B, Sarkar M. Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus in Assam. Indian J Crit Care Med. 2009; 13:156-8.
  27. Kumari N, Mohapatra TM, Singh YI. Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA) in a Tertiary-Care Hospital in Eastern Nepal. J Nepal Med Assoc. 2008; 47(170):53-6.
  28. Dominique S, Blanc, et al. Epidemiology of methicillin resistant Staphylococcus aureus:results of a nation- wide survey in Switzerland. Swiss Med wkly 2002; 132:223-9.
  29. Vandenbroucke-Grauls C. Epidemiology of staphylococcal infections–a European perspective. JAC 1994; 6:67-70.
  30. Begum ES, Anbumani N, Kalyani J, Mallika M. Prevalence and antimicrobial susceptibility pattern of Coagulase-negative Staphylococcus. Int J Med Public Health. 2011; 1(4):59-62.
  31. Irum Perveen, Abdul Majid, Sobia Knawal, Iffat Naz, Shama Sehar, Safia Ahmed et al. Prevalence and antimicrobial susceptibility pattern of Methicillin-Resistant Staphylococcus aureus and coagulase-negative staphylococci in Rawalpindi, Pakistan. Br J Med Med Res. 2013; 3(1):198-209.

 

Table 1: The antibiotic susceptibility pattern for MRSA isolates

Antibiotic

Expected options

Response

 

Antibiotic

Expected options

Response

F

%

F

%

Imipenem

S

10

30

 

 

Moxifloxacin

 

S

0

00

R

18

55

R

25

76

I

5

15

I

8

24

Amoxicillin/ Clavulinic Acid

S

0

00

 

 

Gentamicin

 

S

2

6

R

33

100

R

32

94

I

0

00

I

0

00

Ampicillin/ Sulbactam

 

S

1

6

 

 

Clindamycin

 

S

10

29.5

R

16

94

R

24

70.5

I

0

00

I

0

00

Cefuroxime

 

S

3

9

 

 

Levofloxacin

 

S

0

00

R

31

91

R

35

100

I

0

00

I

0

00

Erythromycin

 

S

10

28.5

 

 

Trimethoprim/

Sulfamethoxazole

S

35

100

R

25

71.5

R

0

00

I

0

00

I

0

0.0

Ciprofloxacin

 

S

1

3

 

 

Linezolid

 

S

31

100

R

33

97

R

0

00

I

0

00

I

0

00

Doxycycline

S

2

5.8

 

 

Vancomycin

 

S

35

100

R

31

91.2

R

0

00

I

1

3

I

0

00

 

Figure 1: Distribution of S. aureus according to sample types

 

 

                  

 

Table 2: The sensitivity pattern of vancomycin and Linezolide within age group

Age group

Vancomycin

The level of

S

R

I

    (P value)

1 - 15 years

2

0

0

 

 

0.74

16 - 30 years

6

0

0

31 - 45 years

7

0

0

46 - 60 years

11

0

0

More than 60 years

8

0

0

 

Linezolide

 

1 - 15 years

2

0

0

0.44

16 - 30 years

6

0

0

31 - 45 years

7

0

0

46 - 60 years

10

0

0

More than 60 years

6

0

0

 

Table 3: The sensitivity pattern of vancomycin and linezolide within hospital department

Hospital Department

Vancomycin

The level of

(P value)

 

S

R

I

 
   

 Medical department

 6

0

0

 

 

0.63

 

 Surgical department

10

0

0

 

 ICU department

 9

0

0

 

 Neurological diseases

 3

0

0

 

 Laboratory department

 6

0

0

 

Hospital Department

   Linezolide

 

 

 Medical department

 5

0

0

0.35

 

 Surgical department

10

0

0

 

 

 ICU department

 8

0

0

 

 Neurological diseases

 2

0

0

 

 Laboratory department

 6

0

0

 

 

 

 

Table 4: The sensitivity pattern of vancomycin and linezolide within sample type

Sample Type

Vancomycin

P-value

S

R

I

 

 Sputum culture

17

0

0

 

 

0.80

 Blood culture

2

0

0

 Pus for culture

3

0

0

 wound swab for culture

12

0

0

 

      Linezolide

 

 Sputum culture

14

0

0

0.23

 Blood culture

2

0

0

 

 Pus for culture

3

0

0

 Wound swab for culture

12

0

0